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Abstract: To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence 
Score®), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low 
(<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion 
than those with high scores (≥31). This was a multicenter chart review of ≥18 year old 
women with pN1mi breast cancer, HER2(−)/ER+ tumors, ductal/lobular/mixed histology, 
with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a 
mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 
22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean 
Recurrence Score was 17.8 (range: 0–50). 48.6% had a mastectomy; 55.8% had a 
lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% 
in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 
80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the 
high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The 
Oncotype DX Recurrence Score result provides actionable information that can be 
incorporated into treatment planning for women with HER2(−)/ER+ pN1mi breast cancer. 
The Recurrence Score result has clinical utility in treatment planning for HER2(−)/ER+ 
pN1mi breast cancer patients. 
Keywords: clinical utility; genomics; recurrence risk; chemotherapy; breast cancer 
 
1. Introduction 
In 2015, more than 231,840 women in the United States will be diagnosed with invasive breast cancer 
and almost 40,290 will die from it, making breast cancer the most common cancer diagnosis among 
American women, as well as the second leading cause of cancer death in women [1]. Advances in breast 
cancer diagnostics and in histopathological and molecular analysis techniques have resulted in an 
increase in the number of women diagnosed with micrometastatic (pN1mi) breast cancer (≤2 mm 
axillary node metastasis) [2–4]. Studies report conflicting results regarding the clinical significance and 
implications of these micrometastases, with some data suggesting they do not confirm increased risk for 
distant recurrence and other data suggesting that they do [4]. 
For women with disease that is human epidermal growth factor receptor 2 (HER2)-negative, 
estrogen receptor (ER) positive (HER2[−]/ER+) and who have micrometastasis, clinical practice varies, 
with some women receiving adjuvant chemotherapy and others prescribed endocrine therapy alone [5]. 
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Node-negative patients treated with tamoxifen alone have a 10-year recurrence rate of 15%, suggesting 
that many women with pN1mi/HER2(−)/ER+ disease could forgo chemotherapy, if those at lowest risk 
could be properly identified [6]. 
The 21-gene assay (Oncotype DX [Genomic Health, Inc., Redwood City, CA, USA]) for invasive 
breast cancer, employs reverse transcriptase polymerase chain reaction (RT-PCR) to measure the 
expression of 16 breast cancer recurrence-related genes and five reference genes from paraffin-
embedded tumor tissue. From this expression profile, a Recurrence Score result ranging from 0 to 100 
is calculated and stratified into low recurrence risk (<18), intermediate recurrence risk (18–30), and 
high recurrence risk (≥31) groups [7]. The prognostic and predictive value of the assay has been 
previously demonstrated in node-negative disease [7,8]. A more recent study using tumor samples 
from patients enrolled in the Southwest Oncology Group-8814 trial also demonstrated the assay’s 
prognostic and predictive value in the node-positive population [9]. 
The test is being used on women with micrometastatic breast cancer, but it is not known whether 
the Recurrence Score result is useful in guiding clinical decisions beyond standard histopathologic 
characteristics. “Clinical utility” describes the ability of a test result to influence patient management 
and, according to the National Comprehensive Cancer Network, must be established for a genomic 
diagnostic assay to be useful in routine clinical practice [10]. To address this gap, we conducted a 
multicenter, medical record review study to determine whether women with HER2(−)/ER+ pN1mi 
breast cancer who have low (<18) Recurrence Score results are given adjuvant chemotherapy in a 
lower proportion than those with high Recurrence Score result (≥31). 
2. Materials and Methods 
2.1. Study Design and Setting 
This study collected data using medical record review and included women with HER2(−)/ER+ 
micrometastatic breast cancer treated at nine breast cancer centers in the United States. The sites were 
selected based on high volume of pN1mi breast cancer patients treated and to reflect a wide variety of 
practice settings and geographic locations. No patient identifiers were collected, and the study was 
granted a waiver of informed consent by the Institutional Review Boards at each institution. 
2.2. Patient Population 
At each of the nine centers, trained abstractors reviewed the medical records of female patients ≥18 
years with HER2(−)/ER+ pN1mi breast cancer; ductal, lobular, or mixed histology; and an Oncotype DX 
Recurrence Score test ordered between January 2007 through December 2012. Patients were excluded 
if they were diagnosed with synchronous contralateral invasive breast cancer, had tubular/colloid or 
metaplastic histology, had an adjuvant chemotherapy recommendation before the Oncotype DX 
Recurrence Score test was ordered, or had more than one Oncotype DX Recurrence Score result. 




Data included patient characteristics, breast cancer surgery type, pathologic data, comorbidities, 
Oncotype DX results, and systemic breast cancer treatment recommended post-Recurrence Score 
result. The primary aim was to determine whether chemotherapy was recommended in lower 
proportion in HER2(−)/ER+ pN1mi breast cancer women with lower Recurrence Score results.  
The medical record abstraction form was designed in conjunction with physician experts (KRF, TGF, 
JSS). To ensure consistent data abstraction across sites, all abstractors received training in correctly 
applying inclusion/exclusion criteria and entering data. Data were collected using a secure, web-based 
application. Regular data quality assurance included checks for content, inconsistencies, and missing 
fields. De-identified data from each site were then combined into a single database. To allow us to 
compare our sample to the larger group of patients on whom the assay was ordered, Genomic Health, 
Inc. provided aggregate data on all pN1mi patients tested nationwide during the same timeframe. 
2.4. Statistical Analysis 
An a priori power calculation was performed. The goal was to have 80% power to detect a 40% 
difference in a recommendation for adjuvant chemotherapy between high and low Recurrence Score 
results using a one-sided test at a significance level of 0.05. The 40% difference was based on the 
assumption that 90% of high Recurrence Score result patients would receive adjuvant chemotherapy, 
compared to 50% of low score patients. The distribution of Recurrence Score results among patients 
tested was assumed approximately 10% high, 30% intermediate, and 60% low risk, based on 
distribution of scores in the Genomic Health, Inc. commercial database. Based on these assumptions, 
175 patient records were required to appropriately power the study. 
All analyses were done in a pooled database, which combined data from each study site, since 
individual sites had too few patients for site-based analyses or comparisons across study sites. 
Descriptive statistics were reported by Recurrence Score result categories (i.e., <18 [low risk], 18–30, 
vs. ≥31 [high risk]). Adjuvant treatment recommendations were summarized as the proportion of 
patients who received the particular treatment recommendation (endocrine therapy, chemotherapy, 
endocrine and chemotherapy combination, specific types of chemotherapy regimens), and these 
summary statistics were presented by the Recurrence Score risk categories. To compare across 
Recurrence Score groups, Chi-square and F-tests were used for categorical and continuous variables, 
respectively. For categorical variables, when some cell counts were less than five, exact Pearson Chi-
square test was used. To compare treatment recommendations, statistical testing was performed both to 
compare across all groups and between the low and high Recurrence Score groups. To determine the 
extent to which our study sample was similar to the broader population of patients tested, we compared 
the distribution of select variables (e.g., patient characteristics, tumor histopathologic characteristics, 
and Recurrence Score results) observed in this study sample with those observed in all pN1mi patients 
in the Genomic Health, Inc. database who had the Oncotype DX test. Missing data were not imputed; 
counts of missing responses for variables were reported. All statistical analyses were performed using 
SAS® version 9.3 (SAS Institute, Cary, NC, USA). 
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3. Results and Discussion 
Medical records for 218 patients were reviewed. Thirty-seven ineligible records were excluded: 17 
did not have micrometastatic disease, 7 did not fall within the required date range, 6 had synchronous 
contralateral invasive cancer, and 7 for a variety of other reasons (e.g., more than one Oncotype DX test, 
inadequate data in the chart to complete abstraction, or left care at the site). Data abstraction was completed 
for 181 female patients with HER2(−)/ER+ pN1mi breast cancer. Overall, the mean Recurrence Score 
result was 17.8 (range: 0–50; median: 16), with 58.6% (n = 106) of patients falling in the low score 
group (<18), 31.5% (n = 57) in the intermediate score group (18–30), and 9.9% (n = 18) in the high score 
group (≥31). Mean patient age was 60.7 years (range: 34–83), and 75.1% were postmenopausal (Table 
1). Most patients had an ECOG performance status of 0 or 1 (82.9% with 0 and 15.5% with 1). The 
most common comorbidities were hypertension (33.7%), osteoporosis/osteopenia (22.7%), osteoarthritis 
(18.8%), type 2 diabetes (8.8%), and chronic obstructive pulmonary disease (5.0%). Only the 
prevalence of coronary artery disease was there noted to be a statistically significant difference at 
baseline between patients in different Recurrence Score risk categories (0.9% in Recurrence Score 
<18, 3.5% in 18–30, and 16.7% in ≥31; p = 0.009) (Table 1). 
Lumpectomy was the most common treatment, performed on 55.8% of patients compared to 48.6% 
women having mastectomy (Table 2). Overall, sentinel lymph node biopsy without axillary lymph node 
dissection was performed in 60.2% of patients; 38.1% of women had a sentinel lymph node biopsy with 
complete axillary node dissection. The proportions with various types of nodal treatment differed 
between groups. Sentinel lymph node biopsy with concurrent axillary node dissection was the most 
common procedure performed in the high Recurrence Score group (66.7%), whereas sentinel lymph 
node biopsy without an axillary node dissection was the most common procedure in the low 
Recurrence Score group (67.9%) (p = 0.041) (Table 2). 
The mean tumor size was 1.8 cm (45.9% had tumor size 1.1–2.0 cm; 33.1% had tumors >2 cm). 
Tumors tended to be larger in the high Recurrence Score group. In patients with a score ≥31, 61.1%  
(n = 11) had tumors >2.0 cm, whereas in the group with a score <18, only 21.7% (n = 23) had tumors of 
that size range (p = 0.002). However, for every tumor size category, there was a wide distribution of 
Recurrence Score results demonstrating that tumor size cannot predict the Recurrence Store result.  
A single focus of tumor was present in 77% (n = 137) of cases, multiple foci in 23% (n = 41), and no 
response was given for three patients. A large majority of patients had tumors with ductal histology 
(84.5%), 11.0% had lobular, and 4.4% had mixed. Tumor focality and histologic type did not differ 
significantly across Recurrence Score groups (Table 2). 
Nottingham Histologic grade was recorded as 1 in 34.3% of tumors, 2 in 48.1% of cases, and 3 in 
17.7%. There were significant differences across the groups, with 61.1% (n = 11) of the high Recurrence 
Score group having grade 3 tumors, compared to 9.4% (n = 10) in the low score group (p < 0.001). 
Results show that for any histologic grade, there was a wide distribution of Recurrence Score results 
indicating that grade alone cannot predict the Recurrence Score result. Lymphovascular invasion was 
present in 61.1% (n = 11) of the tumors in the high Recurrence Score group, compared to 17.0% (n = 18) 
in the low score group (p = 0.010). All groups had 0% that tested positive for HER2, and all tumors 
were ER+ by IHC. In the high score group, 27.8% (n = 5) were PR positive, compared to 99.1%  
(n = 105) in the low score group (p < 0.001) (Table 2). 
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Table 1. Patient characteristics and medical history by Recurrence Score result category.  
 
Recurrence Score <18  
n = 106; 58.6% 
Recurrence Score 18–30  
n = 57; 31.5% 
Recurrence Score ≥31 
n = 18; 9.9% 
Total n = 181 p value a 
 Number Estimate Number Estimate Number Estimate Number Estimate  
Age (years) , mean (SD) [median; range] 106 61.7 (10.2) [61; 34–81] 57 58.3 (10.6) [56; 35–83] 18 62.6 (10.2) [62; 39–81] 181 60.7 (10.4) [60; 34–83] 0.099 
Age (years), n (%)         0.060 
<50 12 (11.3) 13 (22.8) 1 (5.6) 26 (14.4)  
50-64 50 (47.2) 30 (52.6) 12 (66.7) 92 (50.8)  
≥65 44 (41.5) 14 (24.6) 5 (27.8) 63 (34.8)  
ECOG performance status, n (%)         
0.685 
0: fully active 87 (82.1) 48 (84.2) 15 (83.3) 150 (82.9) 
1: restricted activity 18 (17.0) 8 (14.0) 2 (11.1) 28 (15.5)  
2: capable of all self-care 1 (0.9) 1 (1.8) 1 (5.6) 3 (1.7)  
3: capable of only limited self-care 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
4: completely disabled 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
Postmenopausal b, n (%)          
Yes 84 (79.2) 37 (64.9) 15 (83.3) 136 (75.1) 0.091 
Comorbidity, n (%)          
Hypertension 30 (28.3) 22 (38.6) 9 (50.0) 61 (33.7) 0.127 
Osteoporosis/osteopenia 22 (20.8) 15 (26.3) 4 (22.2) 41 (22.7) 0.720 
Osteoarthritis 20 (18.9) 11 (19.3) 3 (16.7) 34 (18.8) 0.999 
Type 2 diabetes 6 (5.7) 8 (14.0) 2 (11.1) 16 (8.8) 0.190 
Chronic obstructive pulmonary disease 6 (5.7) 2 (3.5) 1 (5.6) 9 (5.0) 0.886 
Valvular heart disease 6 (5.7) 2 (3.5) 0 (0.0) 8 (4.4) 0.652 
Coronary artery disease 1 (0.9) 2 (3.5) 3 (16.7) 6 (3.3) 0.009 
Prior invasive breast cancer 2 (1.9) 2 (3.5) 1 (5.6) 5 (2.8) 0.670 
Congestive heart failure 0 (0.0) 1 (1.8) 1 (5.6) 2 (1.1) 0.072 
Type 1 diabetes 0 (0.0) 1 (1.8) 1 (5.6) 2 (1.1) 0.072 
Liver disease 1 (0.9) 0 (0.0) 1 (5.6) 2 (1.1) 0.287 
Elevated creatinine 1 (0.9) 0 (0.0) 1 (5.6) 2 (1.1) 0.287 
Chronic kidney disease 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.6) 0.999 
SD (standard deviation); ECOG (Eastern Cooperative Oncology Group); a p < 0.05 for a statistically significant difference across the three Recurrence Score groups; b Determined by criteria in the NCCN  
Guidelines 2014. 
Pharmaceuticals 2015, 8 113 
 
 
Table 2. Surgical treatment and tumor histopathologic characteristics by Recurrence Score result category. 
 
Recurrence Score <18  
n = 106; 58.6% 
Recurrence Score 18–30  
n = 57; 31.5% 
Recurrence Score ≥31  
n = 18; 9.9% 
Total n = 181 p value a 
 Number Estimate Number Estimate Number Estimate Number Estimate  
Surgical treatment, n (%)          
Lumpectomy 57 (53.8) 34 (59.6) 10 (55.6) 101 (55.8) 0.771 
Mastectomy 52 (49.1) 26 (45.6) 10 (55.6) 88 (48.6) 0.755 
Dissections and biopsies         0.041 
SLNB without ALND 72 (67.9) 31 (54.4) 6 (33.3) 109 (60.2)  
SLNB with ALND 33 (31.1) 24 (42.1) 12 (66.7) 69 (38.1)  
ALND without SLNB 1 (0.9) 2 (3.5) 0 (0.0) 3 (1.7)  
Tumor size (cm), mean (SD) [median; range] 106 1.6 (1.1) [1; 0–6] 57 2.1 (1.2) [2; 1–7] 18 2.3 (0.6) [2; 1–4] 181 1.8 (1.1) [2; 0–7] 0.013 
Tumor size (cm), n (%)         0.002 
≤0.5 9 (8.5) 1 (1.8) 0 (0.0) 10 (5.5)  
0.6–1.0 18 (17.0) 10 (17.5) 0 (0.0) 28 (15.5)  
1.1–2.0 56 (52.8) 20 (35.1) 7 (38.9) 83 (45.9)  
>2.0 23 (21.7) 26 (45.6) 11 (61.1) 60 (33.1)  
Tumor focality, n (%)         0.277 
Number of non-missing 103  57  18  178   
Single focus 75 (72.8) 48 (84.2) 14 (77.8) 137 (77.0)  
Multiple foci 28 (27.2) 9 (15.8) 4 (22.2) 41 (23.0)  
Histologic type, n (%)         
0.184 
Ductal 85 (80.2) 50 (87.7) 18 (100.0) 153 (84.5) 
Lobular 14 (13.2) 6 (10.5) 0 (0.0) 20 (11.0)  
Mixed 7 (6.6) 1 (1.8) 0 (0.0) 8 (4.4)  
Metaplastic or tubular/colloid 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
Overall histologic grade (Nottingham Histologic Score), n (%)         
<0.001 
Grade 1 44 (41.5) 17 (29.8) 1 (5.6) 62 (34.3) 
Grade 2 52 (49.1) 29 (50.9) 6 (33.3) 87 (48.1)  
Grade 3 10 (9.4) 11 (19.3) 11 (61.1) 32 (17.7)  
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Table 2. Cont. 
 
Recurrence Score <18  
n = 106; 58.6% 
Recurrence Score 18–30  
n = 57; 31.5% 
Recurrence Score ≥31  
n = 18; 9.9% 
Total n = 181 p value a 
 Number Estimate Number Estimate Number Estimate Number Estimate  
Evidence of lymphovascular invasion, n (%)         
0.010 
Not identified 67 (63.2) 32 (56.1) 5 (27.8) 104 (57.5) 
Present 18 (17.0) 16 (28.1) 11 (61.1) 45 (24.9)  
Indeterminate 5 (4.7) 2 (3.5) 1 (5.6) 8 (4.4)  
Not reported 16 (15.1) 7 (12.3) 1 (5.6) 24 (13.3)  
HER2 testing by Oncotype DX HER2 score, n (%)         0.999 
Number of non-missing 103  57  18  178   
Negative (<10.7) 102 (99.0) 56 (98.2) 18 (100) 176 (98.9)  
Equivocal (≥10.7 to <11.5) 1 (1.0) 1 (1.8) 0 (0.0) 2 (1.1)  
Positive (≥11.5) 0 (0.0) 0 (0.0) 0 (0.0) 0   
HER2 testing by IHC assay, n (%)         0.922 
Number of non-missing 93  52  16  161   
Negative (0, 1+) 73 (78.5) 40 (76.9) 13 (81.2) 126 (78.3)  
Equivocal (2+) 20 (21.5) 12 (23.1) 3 (18.8) 35 (21.7)  
Positive (3+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
HER2 testing by FISH assay, n (%)         
0.786 
Not amplified (gene copy number <4.0 or ratio <1.8) 71 (67.0) 41 (71.9) 12 (66.7) 124 (68.5) 
Equivocal (gene copy number 4.0–6.0 or ratio 1.8–2.2) 2 (1.9) 0 (0.0) 0 (0.0) 2 (1.1)  
Amplified (gene copy number >6.0 or ratio >2.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
Not performed 33 (31.1) 16 (28.1) 6 (33.3) 55 (30.4)  
ER testing by Oncotype DX ER score, n (%)         
0.072 
Negative (<6.5) 0 (0.0) 1 (1.8) 1 (5.6) 2 (1.1) 
Positive (≥6.5) 106 (100.0) 56 (98.2) 17 (94.4) 179 (98.9)  
Interpretation of ER testing by IHC assay, n (%)         
N/A 
Negative (<1%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Positive (≥1%) 106 (100.0) 57 (100.0) 18 (100.0) 181 (100.0)  
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Table 2. Cont. 
 
Recurrence Score <18  
n = 106; 58.6% 
Recurrence Score 18–30  
n = 57; 31.5% 
Recurrence Score ≥31  
n = 18; 9.9% 
Total  
n = 181 
p value a 
 Number Estimate Number Estimate Number Estimate Number Estimate  
ER testing: % quantitation, mean (SD) [median; range] 98 88.8 (17.3) [95; 9–100] 53 86.9 (20.4) [95; 11–100] 15 83.8 (24.2) [92; 3–100] 166 87.7 (18.9) [95; 3–100] 0.595 
PR testing by Oncotype DX PR score, n (%)         
<0.001 
Negative (<5.5) 1 (0.9) 10 (17.5) 13 (72.2) 24 (13.3) 
Positive (≥5.5) 105 (99.1) 47 (82.5) 5 (27.8) 157 (86.7)  
Interpretation of PR testing by IHC assay, n (%)         <0.001 
Negative (<1%) 3 (2.8) 5 (8.8) 7 (38.9) 15 (8.3)  
Positive (≥1%) 103 (97.2) 52 (91.2) 11 (61.1) 166 (91.7)  
PgR testing: % quantitation, mean (SD) [median; range] 95 78.3 (24.2) [90; 5–100] 48 60.0 (34.9) [73; 1–100] 9 45.1 (35.3) [35; 3–95] 152 70.6 (30.4) [87; 1–100] <0.001 
SLNB (sentinel lymph node biopsy); ALND (axillary lymph node dissection); SD (standard deviation); HER2 (Human Epidermal Growth Factor Receptor 2); IHC (immunohistochemistry); FISH (fluorescence  
in situ hybridization); ER (estrogen receptor); PR (progesterone receptor). a p < 0.05 for a statistically significant difference among the three Recurrence Score result groups. 
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Endocrine therapy was recommended in 91.2% (n = 165) of patients overall, and there was a 
statistically significant difference across Recurrence Score groups (p < 0.029), with a higher percent of 
patients receiving endocrine therapy in lower Recurrence Score groups. Chemotherapy was 
recommended in all 18 patients with high Recurrence Score results, compared to 57.9% (33/57) in the 
intermediate and 19.8% (21/106) in the low score group (p < 0.001 for both the comparison across all 
groups and between the low and high groups). In the low Recurrence Score group, 85 patients (80.2%) 
were recommended endocrine therapy alone, compared to 24 (42.1%) in the intermediate group, and no 
one in the high Recurrence Score group (p < 0.001) (Table 3). 
Comparing our study sample with aggregate data from all pN1mi patients who had a Recurrence 
Score result reported in the US during the same time period revealed no differences in age (mean 60.7 
years in the study sample vs. 59.2 overall), Recurrence Score result (mean 17.8 in the study sample vs. 
17.5 overall), HER2 status (0% positive in the study sample vs. 0.8% overall), ER status (98.9% positive 
vs. 98.6%), and PR status by Oncotype DX (86.7% positive vs. 86.2%) (p > 0.05 for all comparisons) 
(Table 4). 
This multicenter medical record review study examined how the Recurrence Score results may be 
used to inform treatment plans in HER2(−)/ER+ pN1mi breast cancer. We found chemotherapy was 
recommended significantly more often to patients with a high Recurrence Score result than to those 
with a low score. Similarly, endocrine therapy without chemotherapy was never recommended to 
patients in the high Recurrence Score result group, but was recommended to more than 80% of those 
in the low score group. Patients in this study were similar to the larger group of patients who were 
tested with the assay nationwide during the same time period. 
We did not collect information from patient medical records regarding how the Oncotype DX assay 
results were used by physicians in determining the treatment recommendations for patients in this study. 
Based on our prior cognitive interviews with oncologists, the typical process of arriving at treatment 
recommendations with Recurrence Score information may include a review of the patient’s 
clinicopathologic factors, consultations with a multidisciplinary physician group (e.g., tumor board), 
individual physicians (e.g., trusted colleagues), and consideration of the patient’s preference. Our findings 
suggest that clinicians use the Recurrence Score result in determining treatment recommendations for 
patients with HER2(−)/ER+ pN1mi breast cancer, and that the Recurrence Score provides information 
beyond that provided by traditional clinical and pathologic data. When treated with tamoxifen alone, 
pN1mi patients have a low recurrence risk [11], and by forgoing chemotherapy in some patients with low 
scores, physicians may be avoiding unnecessary chemotherapy and its attendant adverse effects [12,13]. 
Although determining cost savings was not a goal of the study, and respondents were not queried about 
cost, it may be that clinicians also consider the economic savings associated with reducing unnecessary 
chemotherapy [14–17]. 
Advances in surgical and analytical techniques have resulted in increased frequency of diagnosis of 
pN1mi disease, but there is still a debate about its prognostic significance. Several studies have found no 
significant difference in overall and/or disease-free survival between patients with micrometastasis and 
those with node-negative disease [18–20], suggesting that the treatment of micrometastatic disease 
should be the same as node-negative disease. The distribution of Recurrence Score results observed in 
the current study is similar to the distribution seen in node-negative patients, providing support for the 
thesis that these patient groups are similar at the level of breast cancer gene expression. Other studies 
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provide evidence that micrometastasic disease does indeed confer a worse prognosis [21,22] and that 
adjuvant therapy may improve disease-free survival [23]. If micrometastatic breast cancer behaves like 
node-positive disease, it may still be possible to eliminate chemotherapy in a lower risk group without 
worsening outcomes through the use of the Recurrence Score result [24]. 
This study was limited by the retrospective design. We were only able to compare proportions of 
patients recommended chemotherapy for the different Recurrence Score result categories, and not the 
change in treatment recommendations from before to after the Oncotype DX result was available. 
While prospective data on this population are unlikely to be forthcoming given the sample sizes and 
period of follow up that would be required for meaningful outcomes, further long term evaluations will 
be assessed in an ongoing phase III randomized clinical trial examining survival outcomes in patients 
with 1–3 positive nodes, HER2(−)/ER+ breast cancer with Recurrence Score of ≤25 undergoing standard 
adjuvant endocrine therapy with or without chemotherapy [25]. Additionally, given the design of our 
study, we were unable to include a control group with treatment recommendations for patients with 
similar stage and type of breast cancer for whom treating physicians did not order the Oncotype DX 
Recurrence Score. We also could not confirm whether distributions of treatment recommendations and the 
actual treatments administered differed in the study subjects since such data were not collected in this 
study, although we would expect such a difference, if any, would be minimal. 
Other limitations include the collection of data at oncology centers chosen purposefully, rather than 
randomly. Because the study was designed to examine the impact of genomic testing on decision-
making, it focused on oncologists who used the test, rather than on a random sample of oncology 
practices around the country. As a result, these findings should apply specifically to those patients for 
whom treatment decision-making was felt to require additional risk assessment. To confirm the 
comparability of the study subjects to a wider population, we compared the study sample to the entire 
patient population of HER2(−)/ER+ pN1mi breast cancer patients on whom the test was ordered 
during the same period. Patient demographics, Recurrence Score results, and pathologic features were 
all similar between the study group and the broader population. Detailed histopathologic data was not 
available for comparison. A final limitation is that the study included data on patients treated from 
2007–2012, covering a period both before and after the test appeared in NCCN treatment guidelines. 
Our estimate of decision impact may therefore be conservative as clinicians may have been less likely 
to base treatment decisions on the results before the assay was included in guidelines [5,8]. 
Although our study has limitations, our results reveal important and novel information about the 
clinical utility of the Oncotype DX Recurrence Score assay in HER2(−)/ER+ pN1mi breast cancer 
patients at oncology practices throughout the US. Additional key information about the Oncotype DX 
assay will be revealed at the conclusion of the two prospective trials, the TAILORx (NCT00310180) and 
the RxPONDER (SWOG S1007; NCT01272037). The TAILORx trial aims to use the Oncotype DX 
assay to determine which women (particularly those with the midrange Recurrence Score of 11–25) 
with early-stage breast cancer, whose tumors are ER-positive and/or PR-positive, HER2(−) and whose 
lymph nodes are negative, would be more likely to benefit from chemotherapy and reduce the use of 
chemotherapy in those who are unlikely to benefit from it. The RxPONDER trial, currently enrolling 
patients with node-positive, ER+, HER2-negative breast cancer who also have low to intermediate 
Oncotype DX Recurrence Score results, aims to assess the benefit, if any, these patients get from the 
addition of chemotherapy to hormone therapy. 
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Table 3. Adjuvant treatment recommendations by Oncotype DX Recurrence Score result. 
 
Recurrence Score <18 
n = 106; 58.6% 
Recurrence Score 18–30  
n = 57; 31.5% 
Recurrence Score ≥31 
n = 18; 9.9% 
Total  
n = 181 
p value a p value b 
 Number Estimate Number Estimate Number Estimate Number Estimate   
Endocrine therapy, n (%) 101 (95.3) 50 (87.7) 14 (77.8) 165 (91.2) 0.029 0.025 
Chemotherapy, n (%) 21 (19.8) 33 (57.9) 18 (100.0) 72 (39.8) <.001 <.001 
Treatment, n (%)         <.001 <.001 
Endocrine therapy without chemotherapy 85 (80.2) 24 (42.1) 0 (0.0) 109 (60.2)   
Chemotherapy without endocrine therapy 5 (4.7) 7 (12.3) 4 (22.2) 16 (8.8)   
Both endocrine therapy and chemotherapy 16 (15.1) 26 (45.6) 14 (77.8) 56 (30.9)   
Patients with recommendation of chemotherapy, n (%) 21  33  18  72    
Chemotherapy regimen recommended, n (%)         0.134 0.016 
BOTH taxane- AND anthracycline-based 9 (42.9) 9 (27.3) 5 (27.8) 23 (31.9)   
Taxane-based, NO anthracycline 5 (23.8) 16 (48.5) 12 (66.7) 33 (45.8)   
Anthracycline-based, NO taxane 0 (0.0) 1 (3.0) 0 (0.0) 1 (1.4)   
Other 7 (33.3) 6 (18.2) 1 (5.6) 14 (19.4)   
a p < 0.05 for a statistically significant difference among the three Recurrence Score result groups. b p <0.05 for a statistically significant difference between Recurrence 
Score <18 and ≥31 groups.  
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Table 4. Comparison of study characteristics with Genomic Health data of pN1mi patients in a comparable time period. 
 Study Data (n = 181) Genomic Health Data a (n = 9328) p-value b 
 Number Estimate Number Estimate  
Age (years), mean (SD) [median; range] 60.7 (10.4) [60; 34–83] 59.2 (10.6) [60; 22–93] 0.055 c 
Age, n (%)     0.130 
<50 years 26 (14.4) 1900 (20.4)  
50–64 years 92 (50.8) 4309 (46.2)  
≥65 years 63 (34.8) 3119 (33.4)  
Oncotype DX Recurrence Score result, mean (SD) [median; range] 17.8 (8.8) [16; 0–50] 17.5 (9.8) [16; 0–100] 0.650 c 
Oncotype DX Recurrence Score result categories, n (%)     0.536 
<18 (low risk) 106 (58.6) 5643 (60.5)  
18–30 (intermediate risk) 57 (31.5) 2965 (31.8)  
≥31 (high risk) 18 (9.9) 720 (7.7)  
HER2 testing by Oncotype DX HER2 score, n (%)     0.567 d 
Negative (<10.7) 176 (98.9) 9147 (98.1)  
Equivocal (≥10.7 to <11.5) 2 (1.1) 103 (1.1)  
Positive (≥11.5) 0 (0.0) 78 (0.8)  
ER testing by Oncotype DX ER score, n (%)     0.778 d 
Negative (<6.5) 2 (1.1) 135 (1.4)  
Positive (≥6.5) 179 (98.9) 9193 (98.6)  
PR testing by Oncotype DX PR score, n (%)     0.848 
Negative (<5.5) 24 (13.3) 1283 (13.8)  
Positive (≥5.5) 157 (86.7) 8045 (86.2)  
SD (standard deviation); ER (estrogen receptor); PR (progesterone receptor). a Selection criteria for Genomic Health, Inc. Data: 1. ER Status specified on requisition = 
positive; 2. Nodal status = “Micromets”; 3. Tumor Type either “Ductal carcinoma, NOS”, “Lobular carcinoma, classic type”, “Lobular carcinoma, solid or alveolar type”, 
“Pleomorphic lobular carcinoma”, or “Invasive carcinoma, mixed pattern”; 4. Requisition date between 1 January 2007 and 31 December 2012; 5. Gender = Female;  
6. World region = Domestic; 7. Patient age ≥18. (Note: Local HER2 status was not specified in the Genomic Health, Inc. data requisition.). b p < 0.05 for a statistically 
significant difference between the study sample and Genomic Health, Inc. data. c Comparison between means. d Pearson exact test. 
 




Gene expression profiles are becoming an integral part of the personalization of cancer care. 
Clinicians who order the Oncotype DX assay for their HER2(−)/ER+ pN1mi breast cancer patients use 
the results of the test to supplement clinical and pathologic information in making treatment 
recommendations. Our study shows that up to 80% of patients with low Recurrence Score results were 
recommended endocrine therapy alone compared to none of the patients with high scores resulting in a 
sparing of exposure to the side effects of chemotherapy in patients with little to no likelihood of benefit 
and providing the appropriate treatment with chemotherapy to the patients with the highest risk of 
distant recurrence. 
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